MesenFlow Technologies SARL

MesenFlow Technologies SARL is rated 3 out of 5 in the category biotechnology. Read and write reviews about MesenFlow Technologies SARL. MesenFlow Technologies has developed a platform for accelerated drug and cosmetic development, using a series of ‘animal-free’ translational medicine techniques. Our platform also has specific applications in product safety analysis, where sophisticated toxicity and inflammatory assessments are required. MesenFlow Technologies was developed by Dr. Paul Bradfield and Professor Beat Imhof for use in research and drug development. Further innovation at the University of Geneva has led to a higher throughput platform that utilised chronic disease tissue engineering, with a higher translational capacity than traditional animal or in-vitro models. This was achieved by the utilisation of human disease tissue and blood, which led to the development of higher-throughput human "organoid"​ models, suitable for commercial use. These have been engineered for use in the discovery and preclinical phase, with specific applications in inflammation, oncology and toxicology. The MesenFlow 'One-Stop'​ service approach is complimentary to existent chemical, drug and cosmetic development strategies, and is easy to use. Compounds can be rapidly screened on our platform to measure toxicity, efficacy, and mechanism-of-action, whilst circumventing issues such as species cross-reactivity. Our methodologies have been proven to give faster results, and provide critical proof-of-concept measurements in the preclinical phase of drug and cosmetic development. We expect to increase the rate of success in the clinical phase for our clients by providing data packages directly relevant to clinical trials, by using our translational technologies. MesenFlow Technologies pushes ahead with a single vision. It is to extend these concepts into all aspects of compound development, where translational medicine techniques have been predicted to increase safety, and radically reduce attrition and costs.